Linden Thomas Advisory Services, LLC Biomarin Pharmaceutical Inc Transaction History

Linden Thomas Advisory Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$83.81 - $99.0 $1,424 - $1,683	17 Added 0.1%	17,900 $1.56 Billion
Q4 2023 Feb 01, 2024	SELL	$76.22 - $98.51 $12,652 - $16,352	-166 Reduced 0.92%	17,883 $1.72 Billion
Q3 2023 Oct 20, 2023	SELL	$85.07 - $94.48 $46,107 - $51,208	-542 Reduced 2.92%	18,049 $1.6 Billion
Q2 2023 Jul 27, 2023	BUY	$86.68 - $100.3 $6,934 - $8,024	80 Added 0.43%	18,591 $1.61 Billion
Q1 2023 Apr 24, 2023	BUY	$87.74 - $117.27 $40,272 - $53,826	459 Added 2.54%	18,511 $1.8 Billion
Q4 2022 Feb 16, 2023	BUY	$80.93 - $108.63 $1.46 Million - $1.96 Million	18,052 New	18,052 $1.87 Billion

638

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Linden Thomas Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Linden Thomas Advisory Services, LLC with notifications on news.